Clinical Trial Update: An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy [Phase 2]

View source ↗

Summary

Open-label extension to assess potential drug-drug interactions between stiripentol or valproate and cannabidiol in epilepsy patients (Phase 2, completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Cannabidiol (cannabidiol)
• Stiripentol (stiripentol)
• Valproate (valproate)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Epilepsy | Phase 2 | Status: COMPLETED